161 results
Page 4 of 9
6-K
EX-1
8le5j dpn45nl01alx
15 Apr 21
BioLineRx Announces Presentation at 2021 American
4:01pm
POS AM
5176qvptsor4et9h zf
23 Feb 21
Prospectus update (post-effective amendment)
9:12am
6-K
EX-99
2ekum6e
23 Feb 21
BioLineRx Reports Year-End 2020 Financial Results
7:02am
6-K
EX-99.1
h4hkwd4m4h7tr9w
22 Jan 21
BioLineRx Announces Closing of $34.5 Million Bought Deal Offering and Full Exercise of
4:21pm
6-K
EX-99.1
0w6mx85m s0m2081luoi
21 Jan 21
Amended and Restated Underwriting Agreement
4:32pm
6-K
EX-99.2
9x802 jor8kg
21 Jan 21
Amended and Restated Underwriting Agreement
4:32pm
424B5
8fh h4lhhq
21 Jan 21
Prospectus supplement for primary offering
4:31pm
FWP
u0j67oa90 3izzjr
19 Jan 21
Free writing prospectus
9:46pm
FWP
xx89y3xbjrt1pajv
19 Jan 21
Free writing prospectus
5:01pm
424B5
ece8p9 ci
19 Jan 21
Prospectus supplement for primary offering
5:00pm
F-3
r54ljz7qxktg
31 Dec 20
Shelf registration (foreign)
4:37pm
6-K
EX-99
mhyyhdun8jnnv fwsh
16 Dec 20
Current report (foreign)
8:00am
6-K
EX-99
qpkh5mda7vtvzffta
16 Dec 20
BioLineRx Announces Final Results from Phase 2a
6:02am
6-K
EX-99
ki74o skw1bydn
23 Nov 20
BioLineRx Reports Third Quarter 2020 Financial Results
7:08am
6-K
EX-99
u69hd04mbf5dmwkb4jx
23 Nov 20
BioLineRx Reports Third Quarter 2020 Financial Results
7:08am
6-K
EX-99
f3f3pq5 sh2
18 Nov 20
BioLineRx Announces Initiation of Phase 1b Clinical Trial
7:09am
6-K
EX-1
71fse
30 Oct 20
BioLineRx Announces Positive Results from Interim Analysis of
7:09am
6-K
EX-99
2s4zjs1rl
29 Oct 20
BioLineRx Announces Initiation of Phase 2 Clinical Trial
8:45am
424B5
fvmj7b4m
25 Sep 20
Prospectus supplement for primary offering
4:30pm